| Ticker | CCCC |
|---|---|
| ISIN | US12529R1077 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also dev...
El precio actual de C4 Therapeutics, Inc. (CCCC) es de 2,88 , con una variación del -3,03%.
C4 Therapeutics, Inc. opera en el sector Healthcare, industria Biotechnology.